International Journal of Gynecologic Cancer最新文献

{"title":"Reviews covering publications from September 30, 2022–March 31, 2023","authors":"","doi":"10.1136/ijgc-34-s2","DOIUrl":"https://doi.org/10.1136/ijgc-34-s2","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"447 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141401452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviews covering publications from March 31, 2020 – September 30, 2020","authors":"K. Lindemann, K. Zalewski, K. J. Halaska, Z. Razumova","doi":"10.1136/ijgc-31-s1","DOIUrl":"https://doi.org/10.1136/ijgc-31-s1","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87047723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviews covering publications from September 30, 2019 - March 31, 2020","authors":"","doi":"10.1136/ijgc-30-s2","DOIUrl":"https://doi.org/10.1136/ijgc-30-s2","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85433206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"17th Biennial Meeting of the International Gynecologic Cancer Society Kyoto, Japan September 14-16, 2018","authors":"P. Cohen, S. Böhm, A. Powell, T. Meniawy, C. Stewart, Max K. Bulsara, C. Gilks, N. Singh","doi":"10.1097/01.IGC.0000546279.09648.02","DOIUrl":"https://doi.org/10.1097/01.IGC.0000546279.09648.02","url":null,"abstract":"Clinical medicine hopes for the development of reliable tumor markers, on the basis of which there can be chosen the optimal treatment program for uterine sarcoma patients, and also make a prognosis. The hyperexpression of PD-L1 in different tumors such as melanoma, kidney cancer, non-small cell lung cancer correlates with unfavorable prognosis of the disease. The role of PD-L1 expression, as a tumor marker in sarcoma, remains unclear. Objective. The investigation of PD-L1 expression as a prognostic tumor marker for uterine sarcoma. Methods. There have been selected 30 uterine sarcoma patients stage I-II (T1-2NxM0), for immunohistochemistry analyze of PD-L1 expression. Depending on the morphological tumor types all the patients were distributed: leiomyosarcoma (LMS) 20.0%, endometrial stromal sarcoma (ESS) 46.7%, undifferentiated sarcoma (HC) 33.3%. Results. Our results showed that 73.3 % of patients with uterine sarcoma showed a low expression level of PD-L1. The moderate level and overexpression of PD-L1 were observed in the undifferentiated and endometrial stromal sarcoma (fig.1) – in 13.3 and 6.7 %, respectively. At further follow-up of patients with PD-L1 expression, the relapse of the disease was detected in 50.0 % of cases. Conclusion. The PD-L1 expression in tumor tissue, regardless of its level, is considered to be an unfavorable prognostic factor for the uterine sarcoma patients. In case of moderate expression level of PD-L1, so as at its overexpression, the tumor progression was detected in 83.3% of uterine sarcoma patients. Fig.1. Moderate expression level of PD-L1 in ESS cells. Reaction from MCAB to PD-L1 (Clone 130021), х400. Copyright ' 2018 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited. 569 Volume 28, Supplement 2, September 2018 POSTER PRESENTATIONS Gynecologic Pathology/Cytology and Disease Pathogenesis IGCS8-0522 RAS GENES IS FREQUENTLY MUTATED IN ENDOMETRIAL POLYPS T. Takeda, K. Banno, M. Yanokura, T. Takahashi, M. Anko, A. Sera, H. Kunitomi, K. Tsuji, Y. Kobayashi, E. Tominaga, D. Aoki Keio University School of Medicine, Obstetrics and Gynecology, Tokyo, Japan Background and Aims: Endometrial polyp is a common disease for women in reproductive age, however a molecular mechanism of endometrial polyp is still unclear. Next-generation sequencer makes whole exome sequencing easier. In this study, we investigated a driver gene of endometrial polyp by next-generation sequencer.","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"13 1","pages":"1 - 1258"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73888580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter From Editor – February 2018","authors":"U. Beller","doi":"10.1097/IGC.0000000000001206","DOIUrl":"https://doi.org/10.1097/IGC.0000000000001206","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"239 1","pages":"207 - 207"},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74726174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study.","authors":"Margherita Dessole, Marco Petrillo, Alessandro Lucidi, Angelica Naldini, Martina Rossi, Pierandrea De Iaco, Simone Marnitz, Jalid Sehouli, Giovanni Scambia, Vito Chiantera","doi":"10.1097/IGC.0000000000000612","DOIUrl":"10.1097/IGC.0000000000000612","url":null,"abstract":"<p><strong>Objectives: </strong>This retrospective, multicentric study investigates quality-of-life issues and emotional distress in gynecological cancer survivors submitted to pelvic exenteration (PE).</p><p><strong>Methods: </strong>The Global Health Status scale of European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30; the EORTC QLQ-CX24 (CX24), and EORTC QLQ-OV28 questionnaires were administered at least 12 months from surgery only in women with no evidence of further recurrence after PE. Statistical analysis was performed by the analysis of variance (for repeated measures.</p><p><strong>Results: </strong>Ninety-six subjects affected by gynecological malignancies receiving PE were enrolled in the study. Anterior PE was performed in 47 patients (49%), posterior PE was performed in 29 cases (30.2%), and total PE performed in 20 women (20.8%). In 38 cases (39.6%), a definitive colostomy was performed. Urinary diversion with continent pouch was created in 11 patients. (11.5%), whereas in the remaining cases, a noncontinent pouch was reconstructed. Patients showed a significant discomfort in attitude to disease (71.5 ± 4.7), body image (48.9 ± 6.4), financial difficulties (56.2 ± 5.8), gastrointestinal symptoms (constipation, 47.8 ± 5.1; diarrhea, 62.4 ± 6.6; appetite loss, 43.6 ± 6.7), insomnia (64.5 ± 6.6), Global Health Status (64.6 ± 3.8), physical functioning (65.8 ± 4.6), role functioning (58.8 ± 5.8), and emotional functioning (67.4 ± 4.2). A higher number of ostomies (hazard rate [HR], 7.613; P = 0.012), the creation of a noncontinent bladder (HR, 8.230; P = 0.009), and of definitive colostomy (HR, 8.516; P = 0.008) emerged as independent predictors of poorer Global Health Status scores. Older age (HR, 11.235; P = 0.003), vaginal/vulvar cancer (HR, 7.369; P = 0.013), total/posterior PE (HR, 7.393; P = 0.013), higher number of ostomies (HR, 7.613; P = 0.012), the creation of a noncontinent bladder (HR, 8.230; P = 0.009), and of definitive colostomy (HR, 8.516; P = 0.008) emerged as independent predictors of lower body image levels.</p><p><strong>Conclusions: </strong>Long-term psycho-oncological support is strongly recommended. The reduction of ostomies seems the most effective way to improve patients' quality of life.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"23 1","pages":"267-273"},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76526915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.","authors":"Jae-Weon Kim, Sven Mahner, Ling-Ying Wu, Tadahiro Shoji, Byoung-Gie Kim, Jian-Qing Zhu, Tadao Takano, Sang-Yoon Park, Bei-Hua Kong, Qiang Wu, Kung-Liahng Wang, Hextan Ys Ngan, Ji-Hong Liu, Li-Hui Wei, Ionel Mitrica, Pingkuan Zhang, Rocco Crescenzo, Qiong Wang, Charles J Cox, Philipp Harter, Andreas du Bois","doi":"10.1097/IGC.0000000000000602","DOIUrl":"10.1097/IGC.0000000000000602","url":null,"abstract":"<p><strong>Objective: </strong>The recent phase 3 trial AGO-OVAR16 demonstrated that pazopanib maintenance improved median progression-free survival in patients with ovarian cancer whose disease did not progress during first-line treatment. However, this improvement was not seen in the subset of East Asian patients. The current analysis evaluated the efficacy and safety of pazopanib maintenance in East Asian patients from AGO-OVAR16 and a separate East Asian study.</p><p><strong>Materials and methods: </strong>East Asian patients from AGO-OVAR16 (n = 209) and the East Asian study (N = 145) were randomized 1:1 to receive pazopanib 800 mg/d or placebo for up to 24 months. The primary end point for each study was progression-free survival by RECIST (Response Evaluation Criteria in Solid Tumors) based on investigator assessment. Clinical and genetics data were analyzed separately by study or pooled according to separate predetermined statistical plans.</p><p><strong>Results: </strong>Pazopanib maintenance had a detrimental effect on median progression-free survival versus placebo in East Asian patients from the combined studies (n = 354; 17.9 vs 21.5 months; hazard ratio, 1.114; 95% confidence interval, 0.818-1.518; P = 0.4928). Pazopanib maintenance showed a disadvantage in overall survival in East Asian patients from AGO-OVAR16 versus placebo (hazard ratio, 1.706; 95% confidence interval, 1.010-2.883; P = 0.0465); overall survival analysis was not performed in the East Asian study because of insufficient event numbers. Pazopanib-treated patients had a significantly higher incidence of grade 3 or higher hypertension (27%) and neutropenia (13%) versus placebo.</p><p><strong>Conclusions: </strong>The treatment effect of maintenance pazopanib in East Asian patients seemed to differ from that in non-Asian patients. In study-specific and pooled analyses, none of the potential factors analyzed could satisfactorily explain the different efficacy results of pazopanib in East Asian patients.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"53 1","pages":"2-10"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73345829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria.","authors":"Michelle M Boisen, J Austin Vargo, Sushi Beriwal, Paniti Sukumvanich, Alexander B Olawaiye, Joseph L Kelley, Robert P Edwards, Marilyn Huang, Madeleine Courtney-Brooks, John T Comerci","doi":"10.1097/IGC.0000000000000614","DOIUrl":"10.1097/IGC.0000000000000614","url":null,"abstract":"<p><strong>Objectives: </strong>Recent data have shown high rates of clinical and pathologic responses to neoadjuvant radiation therapy for locally advanced endometrial cancer. There are limited data on the surgical outcomes of these patients in the era of modern radiation and surgical techniques. We sought to characterize surgical outcomes after extrafascial hysterectomy in this population.</p><p><strong>Methods: </strong>Patients with endometrial cancer of all histologies clinically involving the cervix or parametria treated with neoadjuvant brachytherapy followed by extrafascial hysterectomy from 1999 to 2014 were identified. Patient charts were reviewed for data regarding treatment characteristics and postoperative outcomes. Pearson χ and logistic regression analyses were used to assess correlations between surgical complications and treatment-related variables.</p><p><strong>Results: </strong>Twenty-nine patients met inclusion criteria. Mean operating time for the cohort was 115 minutes. Mean estimated blood loss was 100 mL. No visceral injuries occurred. Mean length of hospital stay was 1 and 4 days for the minimally invasive and laparotomy groups, respectively. Rates of postoperative ileus, blood transfusion, wound infection, and readmission were 3%, 3%, 6%, and 3%, respectively. No case of prolonged urodynamic dysfunction was noted. The rate of vaginal complications was significantly higher in the group of patients who underwent minimally invasive surgery as compared with laparotomy (33% vs 5%, P < 0.041).</p><p><strong>Conclusions: </strong>These data support adjuvant extrafascial hysterectomy after neoadjuvant radiotherapy for endometrial cancer with cervical or parametrial involvement as a safe and viable procedure, with low rates of postoperative complications. Extra care should be taken when closing the vaginal cuff to reduce the risk of vaginal cuff complications.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"39 1","pages":"1149-1154"},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88252648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.","authors":"Stephanie Schneider, Sebastian Heikaus, Philipp Harter, Florian Heitz, Christoph Grimm, Beyhan Ataseven, Sonia Prader, Christian Kurzeder, Thomas Ebel, Alexander Traut, Andreas du Bois","doi":"10.1097/IGC.0000000000000920","DOIUrl":"10.1097/IGC.0000000000000920","url":null,"abstract":"<p><strong>Objective: </strong>The evolving knowledge of ovarian carcinogenesis sets the stage for our understanding of high-grade serous pelvic carcinoma (HGSC). Findings in prophylactic surgery introduced serous tubal intraepithelial carcinoma (STIC) as potential precursor of HGSC. The present study explores whether STIC instead should already be considered as an early stage of HGSC with a need for comprehensive staging and therapy.</p><p><strong>Patients and methods: </strong>We identified all consecutive patients with HGSC who received first-line therapy in our referral center for gynecologic oncology from January 2011 to April 2016. All chemo-naive patients with upfront debulking surgery in whom an association of STIC and tumor lesions could be analyzed were included. Patients with previous removal of the adnexa or overgrown of the fallopian tube by the tumor were excluded. Pathological workup of the fallopian tubes according to the SEE-FIM protocol was conducted.</p><p><strong>Results: </strong>We analyzed a series of 231 consecutive patients with HGSC of whom 121 (52.4%) had ovarian cancer, 74 (32.0%) had cancer of the fallopian tubes and 36 patients (15.6%) had primary peritoneal cancer. Serous tubal intraepithelial carcinoma could be identified in 158 (68.4%) of 231 patients; of 22 patients, 28.1% is ovarian cancer, 30.8% cancer of the fallopian tubes, and 9.5% peritoneal cancer. Four patients without any further intra-abdominal disease were identified of whom 2 patients had stage FIGO IA and 2 patients had lymph node metastases only.</p><p><strong>Conclusions: </strong>Our data suggest that STIC should be regarded as a malignant lesion with metastatic potential. Therefore, we recommend a comprehensive surgical staging including lymphadenectomy.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"21 1","pages":"444-451"},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85391308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morbidity of Staging Inframesenteric Paraaortic Lymphadenectomy in Locally Advanced Cervical Cancer Compared With Infrarenal Lymphadenectomy.","authors":"Clothilde Petitnicolas, Henri Azaïs, Louise Ghesquière, Emmanuelle Tresch-Bruneel, Abel Cordoba, Fabrice Narducci, Lucie Bresson, Eric Leblanc","doi":"10.1097/IGC.0000000000000921","DOIUrl":"10.1097/IGC.0000000000000921","url":null,"abstract":"<p><strong>Objective: </strong>Extended-field chemoradiation is typically used for the management of patients with locally advanced cervical cancer. Given the low rate of skipped metastases above the inferior mesenteric artery, ilioinframesenteric dissection seems to be an acceptable pattern of paraaortic lymph node dissection (LND). Our objective is to compare the surgical morbidity of inframesenteric LND (IM-LND) with infrarenal LND (IR-LND).</p><p><strong>Methods: </strong>In our center, all of the patients with locally advanced cervical cancer and negative magnetic resonance imaging and positron emission tomography-computed tomography imaging at the paraaortic level were offered laparoscopic staging including a diagnostic laparoscopy followed, if negative, by an extraperitoneal paraaortic lymphadenectomy. From January 2011 to September 2015, we included patients who had paraaortic LND from both common iliac bifurcations and divided them into 2 groups according to dissection pattern: to the inferior mesenteric artery (IM-LND) level or to the left renal vein (IR-LND) level. The perioperative and postoperative data were retrospectively recorded.</p><p><strong>Results: </strong>A total of 119 women were included in our study: 56 in the IM-LND group and 63 in the IR-LND group. There was no difference in the patients' characteristics between groups. Regarding the surgical procedure, the operating time was shorter in the IM-LND group than the IR-LND group, 174 ± 50 minutes versus 209 ± 61 minutes (P = 0.001), respectively. There was no significant difference in intra- and postoperative complications, overall survival, or progression-free survival.</p><p><strong>Conclusions: </strong>In our series, exclusive IM-LND surgery is faster than IR-LND and results in similar morbidity and survival rates. These results confirm the feasibility and the applicability of IM-LND to simplify the surgical procedure without impacting survival. More patients should be included in the study to demonstrate the lower rate of morbidity.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"15 1","pages":"575-580"},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88242208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}